KINNATE BIOPHARMA INC (KNTE)
US49705R1059 - Common Stock
Overall KNTE gets a fundamental rating of 2 out of 10. We evaluated KNTE against 588 industry peers in the Biotechnology industry. KNTE has a great financial health rating, but its profitability evaluates not so good. KNTE is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year KNTE has reported negative net income.
In the past year KNTE has reported a negative cash flow from operations.
KNTE had negative earnings in each of the past 5 years.
In the past 5 years KNTE always reported negative operating cash flow.
1.2 Ratios
KNTE's Return On Assets of -64.89% is on the low side compared to the rest of the industry. KNTE is outperformed by 62.35% of its industry peers.
The Return On Equity of KNTE (-70.70%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -64.89% | ||
| ROE | -70.7% | ||
| ROIC | N/A |
ROA(3y)-43.69%
ROA(5y)-30.56%
ROE(3y)-50.27%
ROE(5y)-34.61%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
KNTE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, KNTE has more shares outstanding
KNTE has more shares outstanding than it did 5 years ago.
There is no outstanding debt for KNTE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of 1.00, we must say that KNTE is in the distress zone and has some risk of bankruptcy.
KNTE's Altman-Z score of 1.00 is fine compared to the rest of the industry. KNTE outperforms 64.57% of its industry peers.
There is no outstanding debt for KNTE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 13.19 indicates that KNTE has no problem at all paying its short term obligations.
KNTE has a better Current ratio (13.19) than 86.88% of its industry peers.
KNTE has a Quick Ratio of 13.19. This indicates that KNTE is financially healthy and has no problem in meeting its short term obligations.
KNTE's Quick ratio of 13.19 is amongst the best of the industry. KNTE outperforms 87.05% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 13.19 | ||
| Quick Ratio | 13.19 |
3. Growth
3.1 Past
KNTE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.68%, which is quite good.
EPS 1Y (TTM)8.68%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q50%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
3.2 Future
KNTE is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.70% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y47.95%
EPS Next 2Y28.83%
EPS Next 3Y13.35%
EPS Next 5Y13.7%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
KNTE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KNTE. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
KNTE's earnings are expected to grow with 13.35% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.83%
EPS Next 3Y13.35%
5. Dividend
5.1 Amount
No dividends for KNTE!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
KINNATE BIOPHARMA INC
NASDAQ:KNTE (4/2/2024, 7:25:40 PM)
After market: 2.65 0 (0%)2.65
-0.01 (-0.38%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap125.00M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -64.89% | ||
| ROE | -70.7% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 13.19 | ||
| Quick Ratio | 13.19 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)8.68%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y47.95%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y